23 July 2019
New ICH M10 draft bioanalytical method validation guideline: experts review in exclusive panel discussion
Bioanalysis Zone presents an exciting opportunity to see key experts in the bioanalytical community share their perspectives on the draft ICH M10 guideline, which aims to improve the quality and consistency of bioanalytical data.
Bioanalysis Zone is delighted to offer its members unique access to an insightful panel discussion focused on the new ICH M10 guideline on bioanalytical method validation. The draft guideline provides recommendations on the scientific regulatory requirements for bioanalysis, aiming to improve the quality and consistency of bioanalytical data in support of the development and approval of chemical and biological drugs.
The panel, chaired by Roger Hayes (ICON plc), comprises discussions between leading CRO and pharmaceutical leaders: Corinna Fiorotti (BioAgilytix), Franklin Spriggs (KCAS Bioanalytical and Biomarker Services), Xun Wang (QPS) and Shefali Patel (Johnson and Johnson).
Naamah Maundrell, Senior Editor of Bioanalysis Zone, commented: “The new ICH M10 guideline has taken years to develop and it is great to see the harmonization vision become a reality. The panel discussion features debate on the interpretation, application and implementation of the new guideline – it is certainly one to watch!”
Bioanalysis Zone would also like to take this opportunity to thank the speakers, as well as the sponsors of this panel discussion: BioAgilytix, ICON plc, KCAS Bioanalytical and Biomarker Services and QPS.
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 11,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, peer-reviewed research, exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.
About Future Science Group
Founded in 2001, FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio consists of three imprints, Future Medicine, Future Science and Newlands Press, publishing both eBooks and journals. In addition to this core publishing business, FSG develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.
FSG currently publishes 34 peer-reviewed journals as well as 8 knowledge networks and content hubs across a wide range of therapy area and scientific fields. Key journals include Future Microbiology, Future Oncology and the Journal of Comparative Effectiveness Research, alongside sites such as Infectious Diseases Hub, Oncology Central and The Evidence Base.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.